MSD takes Glenmark to court over sitagliptin ’infringement’
This article was originally published in Scrip
Executive Summary
After a few days of reflection, Merck & Co has retaliated against an attack on one of its major markets for diabetes treatments. The company has filed suit in the Delhi High Court against Glenmark for allegedly violating patents concerning its diabetes therapies, Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), on the Indian market.
You may also be interested in...
Januvia Generics Arrive In India
A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the originator respond with price cuts?
Januvia Generics Arrive: Can MSD Defend Its Turf In India?
A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the company respond with price cuts?
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.